daily multivitamin does not reduce the risks of cvd in men Iron therapy and erythropoiesis-stimulating agents are not always effective for anemia in patients with CKD. Nutritional interventions may be ...

Peter L. Salgo, MD: We’ve been talking around all of this in terms of therapeutic options and transfusions, and I know we’re going to get down in the weeds on this in a little bit. This might be a ...

Anemia is a common complication of stages 3b to 5 CKD. Patients with CKD aren’t always compliant with taking supplemental oral iron, as recommended for the treatment of comorbid anemia. Inflammation ...

Credit: Getty Images. Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat) for the treatment of ...

The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Well, the first step is diagnosis. We have ...

(RTTNews) - The U.S. Food and Drug Administration approved GlaxoSmithKline LLC's Jesduvroq tablets (daprodustat) for anemia caused by chronic kidney disease or CKD for adults who have been receiving ...

Please provide your email address to receive an email when new articles are posted on . Patients with chronic kidney disease and their care partners report a considerable burden, especially when the ...

A proinflammatory diet might increase anemia risk in patients with diabetic kidney disease. Anemia occurs more frequently in patients with diabetic kidney disease (DKD) who have a proinflammatory diet ...

A new study used German data to assess the effects of CKD, anemia, or both on the development and eventual progression of HF among at-risk and symptomatic patients. The prevalence and severity of CKD ...

Daprodustat offers anemia of chronic kidney disease patients a more convenient treatment than the current standard of care. The drug could generate $1 billion in annual sales for the company. The ...